EGFR and non-small cell lung carcinoma: found that neoadjuvant gefitinib was a viable treatment option for stage II-IIIA NSCLC patients with EGFR-mutant, ORR, and MPR were 54.5% and 24.2%, respectively (NCT01833572) (11).